Ducharme is a contributor to TIME. Healthcare workers hold a tablet in front of a COVID-19 coronavirus patient during a video call with relatives at the Intensive Unit Care (ICU) of the Ramon y Cajal ...
Many patients suffer not only from respiratory symptoms due to their COVID-19 disease, but also from significantly reduced physical performance. A patent-protected tablet (CICR-NAM) developed at the ...
Glenmark Pharmaceuticals on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the ...
BENGALURU (Reuters) - Glenmark Pharmaceuticals Ltd said on Monday it would lower the price of its generic version of favipiravir, FabiFlu, to 75 rupees ($0.9983) per tablet for restricted emergency ...
Add Popular Science (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results